BRICS AI-based Clinical Trials Solution Provider Market (Clinical Trial Phase - Phase-I, Phase-II, and Phase-III; Therapeutic Application - Cancer, Cardiovascular Disease, Neurological Disease, Metabolic Disease, Infectious Disease, and Others): BRICS Industry Analysis, Trends, Size, Share and Forecasts to 2028

BRICS AI-based Clinical Trials Solution Provider Market (Clinical Trial Phase - Phase-I, Phase-II, and Phase-III; Therapeutic Application - Cancer, Cardiovascular Disease, Neurological Disease, Metabolic Disease, Infectious Disease, and Others): BRICS Industry Analysis, Trends, Size, Share and Forecasts to 2028

Report Code: BRICS047 Region: BRICS Published: May, 2022

A recent report ongoing by Infinium Global Research on the AI-based clinical trials solution provider market provides in-depth analysis of segments and sub-segments in the BRICS as well as the regional AI-based clinical trials solution provider market. The study also highlights the impact of drivers, restraints, and macro indicators on the BRICS and regional AI-based clinical trials solution provider market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the BRICS AI-based clinical trials solution provider market. According to the report, the BRICS AI-based clinical trials solution provider market is projected to grow at a significant CAGR over the forecast period of 2022-2028.

Market Insight

Artificial Intelligence (AI) is increasingly perceived as a source of opportunities to improve the operational efficiency of clinical trials and minimize clinical development costs. AI is also streamlining the operational processes of clinical trials. AI vendors also help in tracking patient health from their homes, monitoring treatment response, and patient adherence to the trial procedures. By doing that AI companies decrease the risk of patient dropouts, which accounted for 30% on average. Usually, the Phase 3 clinical study stage requires 1000-3000 participants, with a part of them taking a placebo. AI has become a much-needed building block in the clinical research industry and this paper provides an overview of how AI is influencing Clinical Development.

A change in inclination from the usual procedure of medicine development to a technology sourced method, by means of main pharmaceutical companies, is, powering the market growth. Rising alertness and various functions presented by artificial intelligence (AI), in the arena of clinical trials are supporting the enlargement. Lack of personal involvement leads to a rise in unemployment rates to hamper the market growth in the upcoming years. Technological advancements and innovations in AI-based clinical trials solution are providing lucrative opportunities for its market growth.

The clinical trial landscape in BRICS countries is changing. Long heralded as a low-cost alternative to Western markets, Brazil, Russia, India, and China are experiencing a shift in trial initiation by BRICS sponsors. There are 227 AI in Healthcare startups in China. Over the past few years, central government funding and top-down policies have helped to transform Chinese medical research into a data-driven field that uses computer and machine engineering to take pressure off medical workers. NTT DATA is developing a cross-pharmaceutical company/clinical site total solution platform for clinical trials to connect a wide range of clinical trial processes through the most advanced IT technology to help accelerate new drug development. There are 54 AI in Healthcare startups in Brazil. Russia ranks sixth among European countries, with Germany, the UK, Spain, France, and Italy on top of the list of countries with the most ongoing or planned clinical trials.

BRICS AI-based Clinical Trials Solution Provider Market

Segment Covered

The report on BRICS AI-based clinical trials solution provider market covers segments such as clinical trial phase, and therapeutic application. On the basis of clinical trial phase, the sub-markets include phase-I, phase-II, and phase-III. On the basis of therapeutic application, the sub-markets include cancer, cardiovascular disease, neurological disease, metabolic disease, infectious disease, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Unlearn AI Inc, Saama Technologies, Inc, Deep 6 AI, Innoplexus, Symphony AI, Mendel.AI, AiCure, Ardigen, BioSymetrics, and GNS Healthcare.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the BRICS AI-based clinical trials solution provider market. Moreover, the study highlights current market trends and provides forecast from 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


CHOOSE LICENCE TYPE

Please Choose One of them.


$3735.75

$6396.00
© 2022. Infinium Global Research LLP. All Rights Reserved.